Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTPRA | P18433 | 1/20 | 0.48 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TPH1 | P17752 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597769 | 1.00 | TSHR (0.51) | TSHRSMN1; SMN2CYP1A2CYP2D6MAPT | |
| SCHEMBL7437113 | 0.92 | TSHR (0.59) | TSHRSMN1; SMN2CYP1A2CYP2D6MAPT | |
| SCHEMBL121371 | 0.82 | MME (0.58) | ALDH1A1MME | |
| SCHEMBL6716497 | 0.82 | MME (0.58) | ALDH1A1MME | |
| SCHEMBL121370 | 0.82 | MME (0.58) | ALDH1A1MME | |
| SCHEMBL11346818 | 0.82 | MME (0.58) | ALDH1A1MME | |
| SCHEMBL6065430 | 0.82 | MME (0.58) | ALDH1A1MME | |
| SCHEMBL2375620 | 0.82 | TSHR (0.57) | TSHRSMN1; SMN2CYP1A2CYP2D6MAPT | |
| SCHEMBL2375614 | 0.82 | TSHR (0.57) | TSHRSMN1; SMN2CYP1A2CYP2D6MAPT | |
| SCHEMBL28030840 | 0.80 | SMN1; SMN2 (0.54) | TSHRSMN1; SMN2CYP1A2CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3047274-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | Ohmx Corporation (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015042493-A2 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | OHMX CORPORATION (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140134658-A1 | PSA ENZYMATIC ACTIVITY: A NEW BIOMARKER FOR ASSESSING PROSTATE CANCER AGGRESSIVENESS | NOTRHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2571997-A2 | ENZYMATIC ACTIVITY OF PSA AS DIAGNOSTIC MARKER FOR PROSTATE CANCER | Ohmx Corporation (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120034638-A1 | Electrochemical assay for the detection of enzymatically active PSA | NORTHWESTERN UNIVERSITY, AN ILLINOIS NOT FOR PROFIT CORPORATION | 2012-02-09 | — | — | US | disclosed |
| WO-2011146143-A2 | DETECTION OF CANCER BY ASSAYING PSA ENZYMATIC ACTIVITY | OHMX CORPORATION (US) | 2011-11-24 | — | — | WO | disclosed |
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1263473-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | TSHR 3283/4885SMN1; SMN2 2982/4885CYP1A2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.